Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

I will also explain why I upgraded OGN stock to buy from hold, despite the additional uncertainty stemming from the Dermavant ...

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) extended by ...

On October 24, 2024, the Court of Justice of the European Union (CJEU) handed down its highly anticipated ruling in the Kwantum v. Vitra case (C-227/23). In short, the CJEU held that EU Member States ...

3,4 “The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands and ...

With the deal's closure, Organon has added Dermavant’s VTAMA (tapinarof) cream 1%, a US Food and Drug Administration (FDA)-approved nonbiologic, non-steroidal topical treatment, to its portfolio.

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.

Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology. With the acquisition, Organon gains access to VTAMA® (tapinarof) cream, 1%, ...

Business Wire IndiaOrganon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition o ...